Pfizer
Pfizer signs Chinese commercial collaboration
May 9, 2011Sales and Marketing China, Pfizer, Shanghai Pharmaceutical Co
US giant Pfizer looks set to collaborate with Shanghai Pharmaceutical Co. on business opportunities in China. The potential partnership is …
Pfizer sales flat as Lipitor revenues decline
May 4, 2011Sales and Marketing Pfizer
Pfizer’s sales decreased slightly in the first quarter after rising revenues in specialty care and emerging markets failed to offset …
Strides Arcolab facility gets the nod from FDA
May 3, 2011Manufacturing and Production Pfizer, distribution issues
Indian pharmaceutical manufacturer Strides Arcolab has been given a green light from the FDA for a facility in Bangalore that’s …
Deaths reported in Pfizer arthritis trial
April 26, 2011Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib
Four deaths have been reported in a late-stage study of Pfizer’s arthritis drug tofacitinib. Three of the deaths are thought …
Phase III boost for Pfizer’s oral arthritis drug
April 18, 2011Research and Development, Sales and Marketing Pfizer, rheumatoid arthritis, tofacitinib
Pfizer’s rheumatoid arthritis treatment tofacitinib has induced clinical remission of the disease according to one-year data from a phase III …
Pfizer sells drug delivery unit Capsugel for $2.38bn
April 5, 2011Manufacturing and Production Capsugel, Kohlberg Kravis Roberts & Co, Pfizer, pharmaceutical capsules
Pfizer has agreed to sell its Capsugel unit to private equity firm Kohlberg Kravis Roberts & Co. for $2.38 billion …
Digital Pharma: Social media boost for Pfizer anti-counterfeits campaign
March 28, 2011Medical Communications Digital Pharma blog, Pfizer, counterfeits
Pfizer UK is using social media to reinvigorate its Real Danger patient safety campaign. The next phase of the campaign, …
Pfizer’s CRO plans for Sandwich will have limited impact
March 15, 2011Business Services, Research and Development Jobs, Kent, Pfizer, Sandwich, job cuts
Pfizer’s efforts to attract contract research organisations to take over part of its Sandwich research site will only benefit a …
Bayer-helmed oncology biomarker project launched
March 14, 2011Manufacturing and Production, Research and Development AstraZeneca, Bayer, Janssen, Max Planck Institute, Merck, OncoTrack, Pfizer, Roche, biomarkers, oncology
A project to develop the next generation of oncology biomarkers has been launched in Berlin. The pharma industry and European …
Pfizer sells Irish manufacturing facility to Amgen
March 14, 2011Manufacturing and Production Amgen, Dun Laoghaire, Ireland, Pfizer, pharma manufacturing, pharma manufacturing in Ireland
Amgen has come to the rescue of 280 workers whose jobs were threatened by the closure of a manufacturing facility …
Digital Pharma: online campaign directory updated
March 4, 2011Medical Communications, Sales and Marketing Digital Pharma blog, Novartis, Pfizer, Sanofi-Aventis, VTE, diabetes, erectile dysfunction, pharmacist educaiton, venous thromboembolism, viagra
The latest update to the Digital Pharma links directory covers its online campaigns section and includes a pharmacist networking portal …
Universities to ‘pick up pharma’s R&D mantle’ after Pfizer closure
March 3, 2011Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee, UK research, UK science, job cuts
Science in the UK will have to focus on contractually-based research in the future as pharma’s R&D presence in the …
Pfizer drops 15 pipeline projects
March 1, 2011Research and Development Lyrica, Pfizer, Pfizer R&D, Pfizer product pipeline, Pfizer research, inotuzumab, pregabalin
Pfizer has again slimmed down its product pipeline as the US giant looks to cut R&D spending and sharpen its …
Pfizer in break up talks for Sandwich research site
March 1, 2011Research and Development Kent, Pfizer, Sandwich, job cuts
Pfizer is in confidential talks over the future of its Sandwich, Kent research facility that could see the site broken …
David Redfern appointed ViiV chairman
February 28, 2011Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing
David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
